Evogene to Present Its Pharma Division Achievements at the BIO International Convention
Evogene (NASDAQ: EVGN) will present its pharma division achievements at the BIO International Convention in San Diego, held June 22-25, 2026.
Rhea-AI Summary
Evogene (NASDAQ: EVGN) will present its pharma division achievements at the BIO International Convention in San Diego, held June 22-25, 2026. The company will highlight AI-driven small-molecule discovery, including its ChemPass AI platform, and management will be available for one-on-one investor meetings.
Positive
- None.
Negative
- None.
Details
News Market Reaction – EVGN
In the Jun 9 session, EVGN gained 2.40%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Q1 2026 revenue
- $334 thousand
- Revenue from continuing operations quarter ended March 31, 2026
- Prior-year revenue
- $2.343 million
- Revenue from continuing operations quarter ended March 31, 2025
- Q1 2026 net loss
- $5.9 million
- Net loss quarter ended March 31, 2026
- Cash & equivalents
- $8.5 million
- Balance as of March 31, 2026
- Shares outstanding
- 10,412,764 shares
- Ordinary shares issued and outstanding as of March 31, 2026
- Registered resale shares
- 2,446,707 shares
- Ordinary shares registered for resale in 424B3 supplement
- F-3 warrant shares
- 5,076,924 shares
- Ordinary shares issuable upon exercise of warrants under Form F-3
- Warrant cash proceeds
- $6.35 million
- Potential proceeds to company if all F-3 warrants exercised for cash
Historical Context
-
Reported successful first-in-human Phase 1 BMC128 study with preliminary anti-tumor signals.
-
Q1 2026 revenue fell sharply and net loss widened versus prior year.
-
Announced presentation on GenAI molecule design at Schrödinger user group meeting.
-
Scheduled release date and call details for Q1 2026 financial results.
-
Disclosed Nasdaq noncompliance with $1.00 minimum bid price and cure-period timeline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference to be held in
REHOVOT,
Attending the conference on behalf of Evogene will be Ofer Haviv, President and Chief Executive Officer, Dr. Gabi Tarcic, Chief Development Officer and Dr. Olga Nissan, VP Business Development.
At the conference, Evogene will present the latest achievements of its pharma division. Dr. Tarcic will deliver an oral presentation highlighting the company's recent technological and scientific breakthroughs in AI-driven small-molecule discovery and optimization and will share insights into how ChemPass AI™ is enabling new opportunities for collaborative drug discovery with pharmaceutical and biotech partners.
Presentation Details:
- Session: Company Presentation
- Date/Time: Tuesday, June 23, 2026 | 2:00 PM PT
- Location: Theater 1
The company's management will be available for one-on-one meetings at the conference. Interested parties are encouraged to contact Evogene's investor or public relations team.
For more details on the conference, please visit: https://convention.bio.org/.
About Evogene Ltd.
Evogene Ltd. (NASDAQ/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.
At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Forward-Looking Statements:
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses ChemPass AI™ as an enabler of new opportunities for collaborative drug discovery with pharmaceutical and biotech partners. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact
ir@evogene.com
Tel: +972-8-9311901
View original content to download multimedia:https://www.prnewswire.com/news-releases/evogene-to-present-its-pharma-division-achievements-at-the-bio-international-convention-302795111.html
SOURCE Evogene